灰指甲治療市場規模、佔有率、成長分析，按治療類型、適應症、年齡層、性別、配銷通路、地區 - 行業預測，2024-2031

2022年全球灰指甲治療市場規模將為45.2億美元，從2023年的49.1億美元成長到2031年的95億美元，預計在預測期間（2024-2031年）將以複合年成長率成長。年為8.60%）。

由於灰指甲盛行率的不斷增加、治療方案的進步以及人們對該疾病的認知不斷增強，灰指甲治療市場正在顯著成長。這個市場包括多種治療方法，包括外用藥物、雷射治療和口服抗真菌藥物。此外，不斷成長的醫療保健支出正在改善獲得優質治療方法的機會，從而推動市場擴張。然而，高昂的治療成本和與某些治療相關的潛在副作用等挑戰正在限制市場動能。財務障礙可能抑制患者接受治療，特別是雷射治療和Itraconazole和Terbinafine等口服抗真菌藥物等先進治療方法。此外，對這些藥物可能造成肝損傷和胃腸道併發症的擔憂也可能導致患者不願意使用。儘管面臨這些挑戰，但由於藥物開發創新帶來的機遇，包括奈米技術產品和增強的藥物傳輸系統（例如緩釋性製劑和高效的局部治療），市場有望成長。此類技術創新的出現有望改善患者預後並增加趾甲足癬治療在醫療保健領域的吸引力。總體而言，不斷成長的需求和不斷變化的治療方案相互作用，表明灰指甲治療市場充滿活力的未來。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價值鏈分析
• 市場生態系統
• 案例研究分析
• 監管環境
• 創新矩陣
• PESTEL分析
• 主要投資分析
• 關鍵成功因素
• 競爭程度

灰指甲治療市場：依治療類型

• 市場概況
• 藥品
  • 口服
  • RX
  • 在商店
  • 局部的
  • RX
  • OTC
• 雷射
  • CO2消融雷射
  • Nd:YAG雷射
  • 雙波長近紅外線雷射
• 動態療法

灰指甲治療市場：依適應症分類

• 市場概況
• 遠端甲下真菌病
• 白色淺層甲癬
• 近端甲下真菌病
• 念珠菌性甲癬
• 整體性灰指甲

灰指甲治療市場：依年齡層

• 市場概況
• 0-18歲
• 19-39歲
• 40-64歲
• 65歲以上

灰指甲治療市場：性別

• 市場概況
• 男性
• 女士

灰指甲治療市場：按分銷管道

• 市場概況
• 向機構投資者出售
  • 醫院
  • 皮膚科診所
• 零售
  • 零售藥房
  • 藥局
  • 通訊藥局/網上銷售

灰指甲治療市場：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi SA（France）
• Medimetriks Pharmaceuticals, Inc.（US）
• Galderma（Switzerland）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Moberg Pharma AB（Sweden）
• Cardinal Health, Inc.（US）
• Pfizer Inc.（US）
• Almirall, SA（Spain）
• Bayer AG（Germany）
• Viatris Inc.（US）
• GlaxoSmithKline plc（UK）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Evofem Biosciences, Inc.（US）
• Nabriva Therapeutics plc（Ireland）
• Kaken Pharmaceutical Co., Ltd.（Japan）
• Hikma Pharmaceuticals PLC（UK）
• Dermavant Sciences, Inc.（US）
• Sientra, Inc.（US）
• Zynerba Pharmaceuticals, Inc.（US）

Global Onychomycosis Treatment Market size was valued at USD 4.52 billion in 2022 and is poised to grow from USD 4.91 billion in 2023 to USD 9.5 billion by 2031, growing at a CAGR of 8.60% during the forecast period (2024-2031).

The onychomycosis treatment market is witnessing significant growth driven by the increasing prevalence of nail fungal infections, advancements in treatment options, and heightened awareness about the condition. This market encompasses a variety of treatments, including topical solutions, laser therapies, and oral antifungal medications. Additionally, the rise in healthcare expenditure is enhancing accessibility to superior treatment alternatives, further fueling market expansion. However, challenges such as high treatment costs and potential side effects associated with certain therapies are constraining market momentum. Advanced treatments, particularly laser therapies and oral antifungals like itraconazole and terbinafine, may present financial barriers that deter patient uptake. Moreover, concerns over possible liver damage and gastrointestinal complications associated with these medications can contribute to patient reluctance. Despite these challenges, the market is poised for growth, bolstered by opportunities arising from innovations in drug development, including nanotechnology-driven products and enhanced drug delivery systems such as sustained-release formulations and highly efficacious topical treatments. As these innovations emerge, they hold the promise of improving patient outcomes and increasing the attractiveness of onychomycosis treatments in the healthcare landscape. Overall, the interplay of escalating demand and evolving therapeutic options suggests a dynamic future for the onychomycosis treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Treatment Market Segmental Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Onychomycosis Treatment Market

The Global Onychomycosis Treatment market is significantly driven by the increasing prevalence of fungal nail infections, largely attributed to an aging population, rising diabetes rates, and a higher incidence of immunocompromising conditions. As individuals age and comorbidities rise, the susceptibility to onychomycosis escalates, demanding effective treatment options. Additionally, heightened awareness among patients about fungal infections, coupled with improved diagnostic techniques and advanced treatment options being recognized by healthcare professionals, is leading to more accurate diagnoses and subsequent treatments. This confluence of factors not only curtails the stigma associated with fungal infections but also propels market growth as demand for effective therapies surges.

Restraints in the Global Onychomycosis Treatment Market

One prominent market restraint for the Global Onychomycosis Treatment market is the variability in treatment efficacy across diverse patient populations and infection profiles. Many available therapies may not deliver consistent results for all individuals, leading to a significant rate of recurrence, which can diminish patient trust and compliance. Furthermore, treatment effectiveness often hinges on the specific type and severity of the fungal infection, underscoring the imperative for ongoing research and development. This necessity for tailored solutions can hinder market growth, as healthcare providers grapple with the challenge of offering universally effective and reliable treatment options for onychomycosis.

Market Trends of the Global Onychomycosis Treatment Market

The global onychomycosis treatment market is witnessing a significant trend towards the adoption of advanced laser therapies, particularly Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers dominate this segment due to their ability to penetrate deeper into the nail bed, effectively targeting and eradicating stubborn fungal infections. Meanwhile, Blue Light therapies are gaining traction for treating mild cases or as adjunctive treatments, enhancing overall efficacy. With both modalities delivering heat energy to eliminate pathogens, the trend indicates a shift towards non-invasive, effective solutions, appealing to consumers seeking quick recovery with minimal side effects, thereby driving market growth and innovation.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• PESTEL Analysis
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Onychomycosis Treatment Market by Treatment Type

• Market Overview
• Drugs
  • Oral
  • RX
  • OTC
  • Tropical
  • RX
  • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

• Market Overview
• 0 to 18 Years
• 19 to 39 Years
• 40 to 64 Years
• 65 Years & Above

Onychomycosis Treatment Market by Gender

• Market Overview
• Male
• Female

Onychomycosis Treatment Market by Distribution Channel

• Market Overview
• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medimetriks Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moberg Pharma AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermavant Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sientra, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynerba Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments